

amino acid sequence that is at least about 90% similar to the amino acid sequence of SEQ ID NO:2.

148. (Amended) The method of Claim 146 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
149. (Amended) The method of Claim 146 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).
- C₁ 151. (Amended) The method of Claim 146 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).
153. (Amended) The method of Claim 146 wherein said mammalian GPR-9-6 is a human GPR-9-6.
154. (Amended) The method of Claim 146 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
157. (Amended) The method of Claim 156 wherein said cell line is selected from the group consisting of MOLT-4 and MOLT-13.
160. (Amended) The method of Claim 146 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment thereof *in vitro*.
161. (Amended) The method of Claim 146 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment thereof *in vivo*.

162. (Amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a mammalian GPR-9-6 with an antibody or antigen-binding fragment thereof which binds said mammalian GPR-9-6 and inhibits binding of TECK to said mammalian GPR-9-6, wherein said mammalian GPR-9-6 is recognized by mAb 3C3 (ATCC Accession No. HB-12653) and binds TECK.
163. (Amended) The method of Claim 162 wherein said mammalian GPR-9-6 is a human GPR-9-6.
164. (Amended) The method of Claim 162 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.
- C₁ 170. (Amended) The method of Claim 162 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
171. (Amended) The method of Claim 162 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
172. (Amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a mammalian GPR-9-6 with an antibody or antigen-binding fragment thereof which binds said mammalian GPR-9-6 and inhibits binding of TECK to said mammalian GPR-9-6, wherein said mammalian GPR-9-6 is recognized by mAb GPR96-1 (ATCC Accession No. PTA-1470) and binds TECK.
173. (Amended) The method of Claim 172 wherein said mammalian GPR-9-6 is a human GPR-9-6.
174. (Amended) The method of Claim 172 wherein said mammalian GPR-9-6 comprises the amino acid sequence of SEQ ID NO:2.

180. (Amended) The method of Claim 172 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
181. (Amended) The method of Claim 172 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
182. (Amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a GPR-9-6 with an antibody or antigen-binding fragment thereof that has the epitopic specificity of mAb 3C3 (ATCC Accession No. HB-12653), wherein said GPR-9-6 binds TECK and comprises an amino acid sequence that is at least about 90% similar to the amino acid sequence of SEQ ID NO:2.
- C₁ 190. (Amended) The method of Claim 182 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
191. (Amended) The method of Claim 182 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.
192. (Amended) A method of inhibiting a function of GPR-9-6 comprising contacting a cell that expresses a GPR-9-6 with an antibody or antigen-binding fragment thereof that has the epitopic specificity of mAb GPR96-1 (ATCC Accession No. PTA-1470), wherein said GPR-9-6 binds TECK and comprises an amino acid sequence that is at least about 90% similar to the amino acid sequence of SEQ ID NO:2.
200. (Amended) The method of Claim 192 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vitro*.
201. (Amended) The method of Claim 192 wherein said cell that expresses a mammalian GPR-9-6 is contacted with said antibody or antigen-binding fragment *in vivo*.

217. (New) The method of Claim 146 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
218. (New) The method of Claim 146 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
219. (New) The method of Claim 162 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
220. (New) The method of Claim 162 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).
221. (New) The method of Claim 162 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).
222. (New) The method of Claim 162 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
223. (New) The method of Claim 162 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.

224. (New) The method of Claim 172 wherein the binding of said antibody or said antigen-binding fragment to said mammalian GPR-9-6 is inhibited by a peptide that consists of the amino acid sequence of SEQ ID NO:3.
225. (New) The method of Claim 172 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb 3C3 (ATCC Accession No. HB-12653).
226. (New) The method of Claim 172 wherein the binding of said antibody or antigen-binding fragment to said mammalian GPR-9-6 is inhibited by mAb GPR96-1 (ATCC Accession No. PTA-1470).
- C
2 227. (New) The method of Claim 172 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
228. (New) The method of Claim 172 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.
229. (New) The method of Claim 182 wherein said antibody or antigen-binding fragment is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody and an antigen-binding fragment of any one of the foregoing.
230. (New) The method of Claim 182 wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')₂ fragment and a Fv fragment.